222 results on '"Pedersen, Mikkel W."'
Search Results
2. Population genomics of the Viking world
3. First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies
4. Postglacial viability and colonization in North America’s ice-free corridor
5. Archaeal community changes in Lateglacial lake sediments: Evidence from ancient DNA
6. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models
7. Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation
8. Abstract CT274: Individualized APC targeting VB10.NEO cancer vaccines induce broad neoepitope-specific CD8 T cell responses in patients with advanced or metastatic solid tumors: interim results from a phase 1/2a trial
9. Supplementary Materials and Methods from Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
10. Supplementary Materials and Methods from Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers
11. Data from Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
12. Supplementary methods from Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms
13. Supplementary Figure 2 from Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers
14. Data from Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
15. Supplementary Figure Legends from Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers
16. Supplementary Figures 1-7 from Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms
17. Data from Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers
18. Data from Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms
19. Supplementary Tables and Figures from Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
20. Supplementary Figure S1 from Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
21. Supplementary Figure 1 from Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers
22. Supplementary Table S2 from Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
23. Supplementary Figure Legend from Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
24. Supplementary Figures S1-8 from Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
25. Supplementary Tables S1-2 from Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
26. Author Correction: Population genomics of the Viking world
27. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression
28. Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
29. Ancient Human Genomes and Environmental DNA from the Cement Attaching 2,000-Year-Old Head Lice Nits
30. Chiquihuite Cave and America's Hidden Limestone Industries:A Reply to Chatters et al.
31. Ancient Human Genomes and Environmental DNA from the Cement Attaching 2,000-Year-Old Head Lice Nits
32. Targeting the ERBB family in cancer: couples therapy
33. Deep neural networks identify signaling mechanisms of ErbB-family drug resistance from a continuous cell morphology space
34. Chiquihuite Cave and America’s Hidden Limestone Industries: A Reply to Chatters et al.
35. Abstract 1797: Preclinical characterization of Sym024, a novel anti-CD73 antibody
36. Lake Sedimentary DNA Research on Past Terrestrial and Aquatic Biodiversity: Overview and Recommendations
37. Lake Sedimentary DNA Research on Past Terrestrial and Aquatic Biodiversity:Overview and Recommendations
38. Lake Sedimentary DNA Research on Past Terrestrial and Aquatic Biodiversity: Overview and Recommendations
39. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells
40. Hedgehog signaling in small-cell lung cancer: Frequent in vivo but a rare event in vitro
41. Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype
42. Ancient Human Genomes and Environmental DNA from the Cement Attaching 2,000-Year-Old Head Lice Nits.
43. EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes
44. Population genomics of the Viking world:[incl. correction]
45. New Targets for Detection and Treatment of Small Cell Lung Cancer*
46. Shotgun Environmental DNA, Pollen, and Macrofossil Analysis of Lateglacial Lake Sediments From Southern Sweden
47. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform
48. Shotgun Environmental DNA, Pollen, and Macrofossil Analysis of Lateglacial Lake Sediments From Southern Sweden
49. Chiquihuite Cave and America’s Hidden Limestone Industries: A Reply to Chatters et al.
50. Abstract LB-216: Protein pathway activation analysis of a panel of patient-derived epithelial tumor models identifies signatures of response to ErbB1-3 co-targeting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.